Editas Medicine (EDIT) Short-term Investments (2017 - 2025)
Editas Medicine (EDIT) posted quarterly Short-term Investments of $40.0 million for Q2 2025, down 81.39% year-over-year from $214.7 million in Q2 2024, and down 51.43% quarter-over-quarter from $82.3 million in Q1 2025.
Editas Medicine (EDIT) Short-term Investments (2017 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Short-term Investments for 9 consecutive years, with $40.0 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Short-term Investments fell 81.39% year-over-year to $40.0 million; the TTM figure through Jun 2025 stood at $40.0 million (down 81.39% YoY), while the FY2024 annual figure was $138.4 million, down 30.63% from the prior year.
- Short-term Investments slipped to $40.0 million in Q2 2025 per EDIT's latest filing, from $82.3 million in the prior quarter.
- Across five years, Short-term Investments topped out at $298.0 million in Q3 2021 and bottomed at $40.0 million in Q2 2025.
- Historically, Short-term Investments has averaged $213.8 million across 5 years, with a median of $212.9 million in 2023.
- Annual changes were most pronounced in 2021 — Short-term Investments surged 141.56% — and 2025, when it slumped 81.39%.
- Editas Medicine's Short-term Investments stood at $296.3 million in 2021, then sank by 31.58% to $202.8 million in 2022, then fell by 1.62% to $199.5 million in 2023, then slumped by 30.63% to $138.4 million in 2024, then tumbled by 71.12% to $40.0 million in 2025.
- Business Quant data shows EDIT's Short-term Investments at $40.0 million in Q2 2025, $82.3 million in Q1 2025, and $138.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 39.96 Mn |
| Mar 31, 2025 | 82.27 Mn |
| Dec 31, 2024 | 138.37 Mn |
| Sep 30, 2024 | 169.26 Mn |
| Jun 30, 2024 | 214.67 Mn |
| Mar 31, 2024 | 226.94 Mn |
| Dec 31, 2023 | 199.46 Mn |
| Sep 30, 2023 | 267.08 Mn |
| Jun 30, 2023 | 211.15 Mn |
| Mar 31, 2023 | 189.42 Mn |
| Dec 31, 2022 | 202.75 Mn |
| Sep 30, 2022 | 208.91 Mn |
| Jun 30, 2022 | 283.16 Mn |
| Mar 31, 2022 | 277.48 Mn |
| Dec 31, 2021 | 296.33 Mn |
| Sep 30, 2021 | 297.96 Mn |
| Jun 30, 2021 | 272.72 Mn |
| Mar 31, 2021 | 270.42 Mn |
| Dec 31, 2020 | 262.43 Mn |
| Sep 30, 2020 | 215.73 Mn |